Moderna’s COVID-19 vaccine was 100% effective in adolescents aged 12 to 17 in a clinical trial, the company announced Tuesday.
The findings stem from a U.S. study involving over 3,700 kids, called TeenCOVE. Moderna intends to submit the findings to regulators around the world in early June.
“We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents. It is particularly exciting to see that the Moderna COVID-19 vaccine can prevent SARS-CoV-2 infection,” said Stéphane Bancel, CEO of Moderna, in a statement posted Tuesday. “We will submit these results to the U.S. FDA and regulators globally in early June and request authorization. We remain committed to doing our part to help end the COVID-19 pandemic.”
This is a developing story, please check back for updates.